Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: January 22, 2026, 6:56 pm
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 512529 | NSE: SEQUENT

Sequent Scientific Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹171.22Overvalued by 14.82%vs CMP ₹201.00

P/E (203.0) × ROE (3.2%) × BV (₹32.20) × DY (2.00%)

₹66.17Overvalued by 67.08%vs CMP ₹201.00
MoS: -203.8% (Negative)Confidence: 65/100 (Moderate)Models: All 8: Overvalued
ModelCategoryValueWeightSignal
PE-ROEEarnings₹171.6326%Over (-14.6%)
Graham NumberEarnings₹34.7815%Over (-82.7%)
DCFCash Flow₹2.5015%Over (-98.8%)
Net Asset ValueAssets₹18.558%Over (-90.8%)
EV/EBITDAEnterprise₹51.4910%Over (-74.4%)
Earnings YieldEarnings₹16.708%Over (-91.7%)
ROCE CapitalReturns₹45.2110%Over (-77.5%)
Revenue MultipleRevenue₹53.336%Over (-73.5%)
Consensus (8 models)₹66.17100%Overvalued
Key Drivers: P/E of 203 makes PE-ROE unreliable — asset/earnings models are better benchmarks. | ROE 3.2% is below cost of equity.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 0.2%

*Investments are subject to market risks

Investment Snapshot

58
Sequent Scientific Ltd scores 58/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health56/100 · Moderate
ROCE 8.5% AverageROE 3.2% WeakD/E 0.27 Low debtInterest Coverage 0.0x RiskyProfitable 3/5 years Mixed
Smart Money65/100 · Strong
FII holding stable No changeDII holding up 0.90% MF buyingPromoter holding at 52.3% Stable
Earnings Quality65/100 · Strong
OPM expanding (5% → 7%) Improving
Quarterly Momentum80/100 · Strong
Revenue (4Q): +14% YoY GrowingProfit (4Q): +100% YoY Strong
Industry Rank15/100 · Weak
P/E 203.0 vs industry 53.8 Premium to peersROCE 8.5% vs industry 16.4% Below peersROE 3.2% vs industry 15.2% Below peers3Y sales CAGR: 3% Slow

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Sequent Scientific Ltd Investor Signals

Computed from valuation, cash flow, balance sheet, ownership and quarterly trend data already available in this stock page.

Value Trap Score
30/100
Low
Derived from: Cheapness + weak quality + weak cash support
Current data: P/E 203.0 vs Ind 53.8 | ROCE 8.5% | ROE 3.2% | CFO/NP N/A
Balance Sheet Stress
0/100
Comfortable
Derived from: Leverage + debt servicing + liquidity + debt trend
Current data: D/E 0.27x | IntCov 0.0x | Current 1.55x | Borrow/Reserve 0.65x
Cash Flow Reliability
14/100
Weak
Derived from: Cash backing of earnings + working capital pressure
Current data: CFO ₹0 Cr | NP ₹32 Cr | CFO/NP N/A
Ownership Accumulation
-75
Distribution
Derived from: FII + DII + promoter direction, adjusted by crowding
Current data: FII -0.25 pp | DII -0.07 pp | Prom -0.28 pp
Business Momentum
+13
Stable
Derived from: Latest quarter sales + profit + OPM change
Current data: Q Sales -3.9% | Q NP +11.1% | Q OPM +1.0 pp
Derived FieldValueHow it is derived
Valuation Gap %-67.1%((Fair Value - CMP) / CMP) × 100
Borrowings / Reserves0.65xLatest borrowings divided by latest reserves
CFO / Net ProfitN/ALatest operating cash flow divided by latest net profit
FII Change-0.25 ppLatest FII% minus previous FII%
DII Change-0.07 ppLatest DII% minus previous DII%
Promoter Change-0.28 ppLatest promoter% minus previous promoter%
Shareholder Count Change-3,235Latest shareholder count minus previous count
Quarterly Sales Change-3.9%Latest quarter sales vs previous quarter sales
Quarterly Profit Change+11.1%Latest quarter net profit vs previous quarter net profit
Quarterly OPM Change+1.0 ppLatest quarter OPM minus previous quarter OPM

Share Price and Basic Stock Data

Last Updated: January 22, 2026, 6:56 pm

Market Cap 8,768 Cr.
Current Price 201
Intrinsic Value₹66.17
High / Low 260/111
Stock P/E203
Book Value 32.2
Dividend Yield0.00 %
ROCE8.47 %
ROE3.21 %
Face Value 2.00
PEG Ratio841.43

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Sequent Scientific Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Sequent Scientific Ltd 8,768 Cr. 201 260/111203 32.20.00 %8.47 %3.21 % 2.00
Procter & Gamble Health Ltd 7,983 Cr. 4,809 6,739/4,72527.2 3732.60 %47.8 %36.4 % 10.0
Marksans Pharma Ltd 7,615 Cr. 168 271/15521.1 59.30.48 %20.0 %16.8 % 1.00
Sanofi India Ltd 7,513 Cr. 3,262 6,718/3,15121.7 3262.30 %57.5 %43.0 % 10.0
Shilpa Medicare Ltd 7,328 Cr. 375 502/26041.4 1250.13 %7.82 %4.21 % 1.00
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of Sequent Scientific Ltd

Quarterly Result

MetricSep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Sales 338375367333346329361390369391402441424
Expenses 335365370341331307329348330356355389368
Operating Profit 310-3-8152232423934465256
OPM % 1%3%-1%-2%4%7%9%11%11%9%12%12%13%
Other Income 13-60-23107-1306130
Interest 8101110131312161415151414
Depreciation 13141514151516161717161515
Profit before tax -18-10-89-56-3131288162627
Tax % -75%-4%4%-38%123%-617%52%24%20%20%36%31%28%
Net Profit -4-10-92-35-7111966101820
EPS in Rs -0.15-0.36-3.75-1.40-0.340.33-0.040.260.100.140.370.570.59

Last Updated: December 29, 2025, 5:29 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: December 15, 2025, 4:40 am

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 3954436066848481,0391,1791,3621,4131,4211,3701,5511,658
Expenses 3894255506417659141,0091,1501,3031,4091,3081,3901,469
Operating Profit 6185643831251702121091261162189
OPM % 2%4%9%6%10%12%14%16%8%1%4%10%11%
Other Income -5448149436910-011-58-61010
Interest 34433828333336241636486158
Depreciation 29324640414251515256626664
Profit before tax -110-8-14-17444599413753-138-554477
Tax % 1%40%19%-3%3%3%13%24%15%-11%-46%27%
Net Profit -110-12-16-16431578210445-122-303254
EPS in Rs -8.09-0.70-0.78-0.5717.301.972.813.841.65-4.86-1.440.871.67
Dividend Payout % 0%0%0%0%1%10%0%13%0%0%0%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)89.09%-33.33%0.00%2793.75%-86.77%43.86%26.83%-56.73%-371.11%75.41%206.67%
Change in YoY Net Profit Growth (%)0.00%-122.42%33.33%2793.75%-2880.52%130.63%-17.03%-83.56%-314.38%446.52%131.26%

Sequent Scientific Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:13%
5 Years:6%
3 Years:3%
TTM:12%
Compounded Profit Growth
10 Years:46%
5 Years:-21%
3 Years:-19%
TTM:70%
Stock Price CAGR
10 Years:2%
5 Years:6%
3 Years:14%
1 Year:1%
Return on Equity
10 Years:8%
5 Years:2%
3 Years:-3%
Last Year:3%

Last Updated: September 5, 2025, 1:26 pm

Balance Sheet

Last Updated: December 4, 2025, 1:56 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 27304849494950505050505050
Reserves 3061898928599657637678642649607654759
Borrowings 418473312416305325343277365444488481490
Other Liabilities 148343265503380346424381378374389412427
Total Liabilities 6239081,5231,8961,3321,3781,4541,3861,4351,5171,5341,5981,726
Fixed Assets 238474586684476498577536564605592586628
CWIP 4339243318231331125516165
Investments 05942842823918017183380400
Other Assets 3423364857515996776937378218569229961,093
Total Assets 6239081,5231,8961,3321,3781,4541,3861,4351,5171,5341,5981,726

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + -45-24-0-74511611511531173183
Cash from Investing Activity + -81-157-310-1167-68-7210-94-65-6-25
Cash from Financing Activity + 146179309147-57-20-43-1396732-1-61
Net Cash Flow 20-1-224-5280-144-1623-2

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-412.00-455.00-256.00-373.00-222.00-200.00-173.00-65.00-256.00-432.00-427.00-319.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 779511613611198999385888985
Inventory Days 175153164165125134132139160152166173
Days Payable 198147175208127141133119119107121115
Cash Conversion Cycle 54101105931109298112126132135143
Working Capital Days -162-11165-252033295154463070
ROCE %-4%8%2%1%40%9%12%16%6%-3%0%8%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Promoters 52.79%52.79%52.79%52.79%52.79%52.79%52.78%52.76%52.61%52.61%52.61%52.33%
FIIs 6.25%5.89%6.27%6.03%6.12%6.16%5.69%6.45%6.10%6.05%6.15%5.90%
DIIs 2.81%2.92%2.92%3.23%7.23%7.59%8.06%9.99%12.01%12.82%12.98%12.91%
Public 37.76%38.00%37.64%37.57%33.69%33.29%33.30%30.63%29.12%28.36%28.10%28.69%
Others 0.39%0.39%0.39%0.39%0.17%0.17%0.17%0.17%0.16%0.16%0.16%0.16%
No. of Shareholders 1,96,2311,91,8751,87,4741,84,5211,72,8531,66,5931,63,6931,54,6031,62,5741,58,1521,47,3201,44,085

Shareholding Pattern Chart

No. of Shareholders

Sequent Scientific Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Quant Small Cap Fund 22,502,050 1.67 502.8310,788,9252025-12-07 16:44:07108.57%
UTI Healthcare Fund 871,145 1.73 19.47620,3052025-12-07 16:44:0740.44%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 2.002.002.002.002.00
Basic EPS (Rs.) 0.88-1.44-4.881.673.87
Diluted EPS (Rs.) 0.85-1.44-4.881.653.85
Cash EPS (Rs.) 3.941.28-2.663.876.24
Book Value[Excl.RevalReserv]/Share (Rs.) 28.1528.5830.0429.4431.26
Book Value[Incl.RevalReserv]/Share (Rs.) 28.1528.5830.0429.4431.26
Revenue From Operations / Share (Rs.) 61.9854.9156.9756.8854.82
PBDIT / Share (Rs.) 7.052.900.734.848.88
PBIT / Share (Rs.) 4.400.43-1.502.786.84
PBT / Share (Rs.) 1.77-2.19-5.522.155.50
Net Profit / Share (Rs.) 1.29-1.19-4.891.814.21
NP After MI And SOA / Share (Rs.) 0.87-1.44-4.861.663.84
PBDIT Margin (%) 11.375.281.298.5116.18
PBIT Margin (%) 7.090.79-2.624.8912.47
PBT Margin (%) 2.85-3.98-9.683.7710.03
Net Profit Margin (%) 2.07-2.16-8.583.187.67
NP After MI And SOA Margin (%) 1.41-2.61-8.522.917.00
Return on Networth / Equity (%) 3.10-5.46-17.336.0313.11
Return on Capital Employeed (%) 10.031.18-3.727.4418.22
Return On Assets (%) 1.36-2.32-7.922.866.85
Long Term Debt / Equity (X) 0.380.210.260.170.12
Total Debt / Equity (X) 0.630.680.560.460.27
Asset Turnover Ratio (%) 0.980.890.170.170.20
Current Ratio (X) 1.731.311.501.541.55
Quick Ratio (X) 0.960.760.840.850.97
Inventory Turnover Ratio (X) 4.241.770.570.740.87
Interest Coverage Ratio (X) 2.901.500.517.629.04
Interest Coverage Ratio (Post Tax) (X) 1.610.74-0.613.865.65
Enterprise Value (Cr.) 3717.123313.782217.183626.836172.31
EV / Net Operating Revenue (X) 2.402.421.562.574.53
EV / EBITDA (X) 21.0645.79120.8630.1628.00
MarketCap / Net Operating Revenue (X) 2.112.101.272.354.39
Price / BV (X) 4.654.382.594.868.22
Price / Net Operating Revenue (X) 2.112.101.272.354.39
EarningsYield 0.01-0.01-0.060.010.01

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Sequent Scientific Ltd. is a Public Limited Listed company incorporated on 28/06/1985 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L99999MH1985PLC036685 and registration number is 036685. Currently Company is involved in the business activities of Manufacture of veterinary preparations. Company's Total Operating Revenue is Rs. 178.26 Cr. and Equity Capital is Rs. 50.06 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
Pharmaceuticals3rd Floor, Srivalli�s Corporate, Hyderabad Telangana 500033Contact not found
Management
NamePosition Held
Dr. Kamal K SharmaChairman & Ind.Director
Mr. Rajaram NarayananManaging Director & CEO
Mr. Vedprakash RagateExecutive Director
Mr. Gregory AndrewsNon Executive Director
Mr. Neeraj BharadwajNon Executive Director
Dr. Fabian KauscheNon Executive Director
Dr. Hari Babu BodepudiNon Executive Director
Mr. Milind SarwateIndependent Director
Ms. Revati KastureIndependent Director

FAQ

What is the intrinsic value of Sequent Scientific Ltd and is it undervalued?

As of 07 April 2026, Sequent Scientific Ltd's intrinsic value is ₹66.17, which is 67.08% lower than the current market price of ₹201.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (3.21 %), book value (₹32.2), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Sequent Scientific Ltd?

Sequent Scientific Ltd is trading at ₹201.00 as of 07 April 2026, with a FY2026-2027 high of ₹260 and low of ₹111. The stock is currently in the middle of its 52-week range. Market cap stands at ₹8,768 Cr..

How does Sequent Scientific Ltd's P/E ratio compare to its industry?

Sequent Scientific Ltd has a P/E ratio of 203, which is above the industry average of 53.84. This significantly elevated P/E suggests the market expects strong future growth, or the stock may be overpriced relative to current earnings.

Is Sequent Scientific Ltd financially healthy?

Key indicators for Sequent Scientific Ltd: ROCE of 8.47 % is on the lower side compared to the industry average of 16.35%; ROE of 3.21 % is below ideal levels (industry average: 15.16%). Dividend yield is 0.00 %.

Is Sequent Scientific Ltd profitable and how is the profit trend?

Sequent Scientific Ltd reported a net profit of ₹32 Cr in Mar 2025 on revenue of ₹1,551 Cr. Compared to ₹45 Cr in Mar 2022, the net profit shows a declining trend.

Does Sequent Scientific Ltd pay dividends?

Sequent Scientific Ltd has a dividend yield of 0.00 % at the current price of ₹201.00. The company is currently not paying meaningful dividends.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Sequent Scientific Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports